The Catalyst Brief
Coverage

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.

Page 16 of 34

Archive

FDA Misses Deadline on Electric Shock Device Ban, Sparking Outcry from Disability AdvocatesJun 1, 2026

FDA Misses Deadline on Electric Shock Device Ban, Sparking Outcry from Disability Advocates

In a controversial decision, the FDA has missed the deadline to implement a ban on the use of electric shock devices on people with intellectual disabilities. This delay intensifies concerns among advocates who argue that such devices pose severe ethical and medical risks. The regulatory implications of this missed deadline could shape future policies on disability rights and medical practices.

Michael TorresMichael Torres
Medicare’s Silence on GLP-1 Obesity Drug Coverage Raises Concerns Amid Massachusetts Legal ActionJun 1, 2026

Medicare’s Silence on GLP-1 Obesity Drug Coverage Raises Concerns Amid Massachusetts Legal Action

As Medicare prepares to offer GLP-1 drugs like Wegovy and Zepbound to older adults for $50 a month beginning in July, the agency remains silent on how this program will impact taxpayer costs. Simultaneously, Massachusetts has filed a lawsuit against United Healthcare, escalating healthcare coverage tensions in the state. These developments highlight the complex interplay between federal drug coverage policies and state-level healthcare regulatory actions.

Emily CarterEmily Carter
FDA Relaxation Spurs Surge of Unvetted Blood Pressure Wearables in the MarketMay 28, 2026

FDA Relaxation Spurs Surge of Unvetted Blood Pressure Wearables in the Market

In response to new FDA wellness guidance, a flood of wearable devices with unvalidated blood pressure measurement technology has entered the consumer market, raising concerns about accuracy and safety. This development underscores the complex balance regulators face in fostering innovation while ensuring public health.

Dr. Priya NandakumarDr. Priya Nandakumar
FDA Assembles Vaccine Experts to Update COVID-19 Formulation Amid New DevelopmentsMay 27, 2026

FDA Assembles Vaccine Experts to Update COVID-19 Formulation Amid New Developments

In a move that underscores the evolving nature of the COVID-19 pandemic response, the FDA has assembled a panel of vaccine experts to reevaluate and update the seasonal COVID-19 vaccine formulation. This development comes in the context of significant changes to vaccine advisory committees following recent political and health sector shifts.

Emily CarterEmily Carter
AstraZeneca’s Breast Cancer Drug Camizestrant Faces FDA Advisory Committee Vote SetbackMay 27, 2026

AstraZeneca’s Breast Cancer Drug Camizestrant Faces FDA Advisory Committee Vote Setback

AstraZeneca’s efforts to gain FDA approval for camizestrant, an oral selective estrogen receptor degrader (SERD), have been met with challenges following a negative vote by an FDA advisory committee. This decision introduces uncertainty around the drug’s regulatory timeline and highlights the rigorous scrutiny that new cancer therapies undergo before approval.

Jonathan BlakeJonathan Blake

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.